Go to CARVYKTI® (ciltacabtagene autoleucel) HCP homepage
  • About CARVYKTI®
    How CARVYKTI® works
    Manufacturing CARVYKTI®
  • CARVYKTI® Efficacy
    CARTITUDE-4
    Primary Analysis
    Study Design
    Progression-Free Survival (PFS)
    Overall Survival (OS)
    Depth of Response
    Duration of Response
    Time to Next Treatment (TTNT)
    CARTITUDE-4
    Follow-Up Analysis
    Progression-Free Survival (PFS)
    Overall Survival (OS)
    Depth of Response
    Duration of Response
    CARTITUDE-1
    Primary Analysis
    Study Design
    Depth of Response
    Duration of Response
    Time To Response
    CARTITUDE-1
    5-year Follow-Up Analysis
    5-Year Baseline Characteristics
    5-Year Duration Of Response
  • CARVYKTI® Safety
    Boxed Warning
    Cytokine Release
    Syndrome (CRS)
    Neurologic Toxicities
    Hemophagocytic
    Lymphohistiocytosis (HLH)
    Prolonged and/or
    Recurrent Cytopenias
    Immune Effector Cell-Associated Enterocolitis
    Secondary Malignancies
    Additional Warnings & Precautions, and ARs ≥10%
    Long-Term Safety
  • Treatment Process
    Patient Identification
    Steps in the Treatment Process
  • Resources
    For Physicians
    For Nurses/APPs
    For Patients/Care Partners
    Patient Support Program
    For Access and Reimbursement Support
    For Order Management
  • Urgency to Treat Earlier
    Attrition Rates
    T-cell Fitness and
    Bridging Therapy
  • Treatment Centers
  • Coverage Lookup
  • Get In Touch
  • CARVYKTI® Prescribing Information
  • Contact Us
  • Go To Patient Website
  • Prescribing Information
    CARVYKTI® PRESCRIBING INFORMATION
    CARVYKTI® LA INFORMACIÓN DE PRESCRIPCIÓN
  • Get In Touch
  • Contact Us
  • For US Healthcare Professionals
  • Go To Patient Website
Treatment CentersCoverage Lookup

CARVYKTI® INSURANCE COVERAGE INFORMATION

99% OF COMMERCIAL & MEDICARE LIVES COVERED*

Please select a state, plan type, or payer to see and download coverage details for CARVYKTI®.

Clear all

Clear all

Clear all

Disclaimer
Not all plans that cover CARVYKTI® are listed. Coverage relevant to your patients may vary. Status is representative of the coverage for the majority of members covered under each plan.This information does not give advice or promise coverage or payment. Legal requirements and plan information can be updated frequently. Contact the plan for more information about current coverage, restrictions, or requirements that may apply. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced herein. This communication is solely the responsibility of Janssen Biotech, Inc.

*Collected in 11/24 and may change. This percentage accounts for medical benefit only and may not represent 100% of formulary lives due to data limitations.

Download Resources For Healthcare Professionals And Supporting Staff

VIEW REIMBURSEMENT RESOURCES

GET IN
TOUCH
SCROLL TO TOP ↑

References

  1. Data on file. Janssen Biotech, Inc.
  2. CARVYKTI® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.1.2025. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed January 31, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.